Current treatment of severe asthma

Clinical and Experimental Allergy

Volumn 42, Issue 5, 2012, Pages 693-705

  Hashimoto, S ^a   Bel, E H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; MEPOLIZUMAB; PREDNISOLONE; THEOPHYLLINE;

ALLERGIC ASTHMA; ASTHMA; DISEASE SEVERITY; HUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RADIOFREQUENCY; REVIEW; THERMOPLASTY;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; HYPERTHERMIA, INDUCED; PHENOTYPE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84859977447     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03936.x     Document Type: Review

References (204)

1. Anon. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341-51.
2. Anderson GP Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-19.
3. Bel EH, Sousa A, Fleming L et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910-7.
4. Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926-38.
5. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22:478-83.
6. Heaney LG, Conway E, Kelly C et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003; 58:561-6.
7. Clerisme-Beaty EM, Bartlett SJ, Teague WG et al. The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma. J Allergy Clin Immunol 2011; 127:406-11.
8. Gamble J, Stevenson M, McClean E, Heaney LG The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180:817-22.
9. Greaves CJ, Hyland ME, Halpin DMG, Blake S, Seamark D Patterns of corticosteroid medication use: non-adherence can be effective in milder asthma. Prim Care Respir J 2005; 14:99-105.
10. Williams LK, Pladevall M, Xi H et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114:1288-93.
11. Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695-707.
12. Horne R, Weinman J Self-regulation and self management in asthma: exploring the role of illness perceptions and treatments beliefs in explaining non-adherence to preventer medication. Psychol Health 2002; 17:17-32.
13. Williams LK, Joseph CL, Peterson EL et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007; 120:1153-9.
14. Aburuz S, Heaney LG, Millership J, Gamble J, McElnay J A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma. Br J Clin Pharmacol 2007; 63:110-5.
15. Gamble J, Stevenson M, Heaney LG A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011; 105:1308-15.
16. Horne R Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130:65S-72S.
17. Kolbe J, Vamos M, Fergusson W, Elkind G, Garrett J Differential influences on asthma self-management knowledge and self-management behavior in acute severe asthma. Chest 1996; 110:1463-8.
18. Chan-Yeung M, Malo JL Occupational asthma. N Engl J Med 1995; 333:107-12.
19. Kogevinas M, Antó JM, Sunyer J, Tobias A, Kromhout H, Burney P Occupational asthma in Europe and other industrialised areas: a population-based study. European Community Respiratory Health Survey Study Group. Lancet 1999; 353:1750-4.
20. Boulet LP, Lemiere C, Gautrin D, Cartier A New insights into occupational asthma. Curr Opin Allergy Clin Immunol 2007; 7:96-101.
21. de Groene GJ, Pal TM, Beach J et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2011; 5:CD006308.
22. Gautrin D, Ghezzo H, Infante-Rivard C et al. Long-term outcomes in a prospective cohort of apprentices exposed to high-molecular-weight agents. Am J Respir Crit Care Med 2008; 177:871-9.
23. Moscato G, Pala G, Boillat MA et al. EAACI Position Paper: prevention of work-related respiratory allergies among pre-apprentices or apprentices and young workers. Allergy 2011; 66:1164-73.
24. Call RS, Ward G, Jackson S, Platts-Mills TA Investigating severe and fatal asthma. J Allergy Clin Immunol 1994; 94:1065-72.
25. Peat JK, Tovey E, Toelle BG et al. House dust mite allergens. A major risk factor for childhood asthma in Australia. Am J Respir Crit Care Med 1996; 153:141-6.
26. Rosenstreich DL, Eggleston P, Kattan M et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336:1356-63.
27. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27:615-26.
28. Matsuoka H, Niimi A, Matsumoto H et al. Specific IgE response to trichophyton and asthma severity. Chest 2009; 135:898-903.
29. Neukirch C, Henry C, Leynaert B, Liard R, Bousquet J, Neukirch F Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999; 103:709-11.
30. Arshad SH Environmental control for secondary prevention of asthma. Clin Exp Allergy 2010; 40:2-4.
31. Gotzsche PC, Johansen HK House dust mite control measures for asthma. Cochrane Database Syst Rev 2008; 2:CD001187.
32. Platts-Mills TA Allergen avoidance in the treatment of asthma and rhinitis. N Engl J Med 2003; 349:207-8.
33. Boner AL, Bodini A, Piacentini GL Environmental allergens and childhood asthma. Clin Exp Allergy 1998; 28(Suppl 5):76-81.
34. Grootendorst DC, Dahlen SE, Van Den Bos JW et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin Exp Allergy 2001; 31:400-8.
35. Custovic A, Simpson A, Chapman MD, Woodcock A Allergen avoidance in the treatment of asthma and atopic disorders. Thorax 1998; 53:63-72.
36. National Institutes of Health, National Heart, Lung, and Blood Institute, Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 2008. (accessed July 2011).
37. Anon. National Asthma Education and Prevention Program, Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2010; 120:94-138.
38. Platts-Mills TA Allergen avoidance in the treatment of asthma: problems with the meta-analyses. J Allergy Clin Immunol 2008; 122:694-6.
39. Eisner MD, Yelin EH, Katz PP, Earnest G, Blanc PD Exposure to indoor combustion and adult asthma outcomes: environmental tobacco smoke, gas stoves, and woodsmoke. Thorax 2002; 57:973-8.
40. Balmes JR, Earnest G, Katz PP et al. Exposure to traffic: lung function and health status in adults with asthma. J Allergy Clin Immunol 2009; 123:626-31.
41. Gauderman WJ, Avol E, Lurmann F et al. Childhood asthma and exposure to traffic and nitrogen dioxide. Epidemiology 2005; 16:737-43.
42. Mamessier E, Nieves A, Vervloet D, Magnan A Diesel exhaust particles enhance T-cell activation in severe asthmatics. Allergy 2006; 61:581-8.
43. McCreanor J, Cullinan P, Nieuwenhuijsen MJ et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med 2007; 357:2348-58.
44. Sunyer J, Basagana X, Belmonte J, Anto JM Effect of nitrogen dioxide and ozone on the risk of dying in patients with severe asthma. Thorax 2002; 57:687-93.
45. Fauroux B, Sampil M, Quenel P, Lemoullec Y Ozone: a trigger for hospital pediatric asthma emergency room visits. Pediatr Pulmonol 2000; 30:41-6.
46. Weinmayr G, Romeo E, De Sario M, Weiland SK, Forastiere F Short-term effects of PM10 and NO2 on respiratory health among children with asthma or asthma-like symptoms: a systematic review and meta-analysis. Environ Health Perspect 2010; 118:449-57.
47. Comhair SA, Gaston BM, Ricci KS et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PLoS ONE 2011; 6:e18574.
48. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J 2000; 15:470-7.
49. Livingston E, Thomson NC, Chalmers GW Impact of smoking on asthma therapy: a critical review of clinical evidence. Drugs 2005; 65:1521-36.
50. Ricciardolo FL, Di Stefano A Corticosteroid resistance in smokers with asthma. Am J Respir Crit Care Med 2004; 169:1252-3.
51. Thomson NC, Chaudhuri R, Livingston E Asthma and cigarette smoking. Eur Respir J 2004; 24:822-33.
52. Chaudhuri R, Livingston E, McMahon AD et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174:127-33.
53. Rayens MK, Burkhart PV, Zhang M et al. Reduction in asthma-related emergency department visits after implementation of a smoke-free law. J Allergy Clin Immunol 2008; 122:537-41.
54. Mackay D, Haw S, Ayres JG, Fischbacher C, Pell JP Smoke-free legislation and hospitalizations for childhood asthma. N Engl J Med 2010; 363:1139-45.
55. Stenfors N, Nordenhall C, Salvi SS et al. Different airway inflammatory responses in asthmatic and healthy humans exposed to diesel. Eur Respir J 2004; 23:82-6.
56. Avol EL, Gauderman WJ, Tan SM, London SJ, Peters JM Respiratory effects of relocating to areas of differing air pollution levels. Am J Respir Crit Care Med 2001; 164:2067-72.
57. Bayer-Oglesby L, Grize L, Gassner M et al. Decline of ambient air pollution levels and improved respiratory health in Swiss children. Environ Health Perspect 2005; 113:1632-7.
58. Renzetti G, Silvestre G, D'Amario C et al. Less air pollution leads to rapid reduction of airway inflammation and improved airway function in asthmatic children. Pediatrics 2009; 123:1051-8.
59. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; 4:CD003534.
60. Reddel HK, Jenkins CR, Marks GB et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16:226-35.
61. Tayab ZR, Fardon TC, Lee DK et al. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol 2007; 64:698-705.
62. Lipworth BJ Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-55.
63. Lipworth BJ The comparative safety/efficacy ratio of HFA-BDP. Respir Med 2000; 94(Suppl D):S21-6.
64. Mortimer KJ, Tata LJ, Smith CJ et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61:405-8.
65. Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-8.
66. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1:171-5.
67. Hall IP The beta-agonist controversy revisited. Lancet 2004; 363:183-4.
68. Tattersfield AE Current issues with beta2-adrenoceptor agonists: historical background. Clin Rev Allergy Immunol 2006; 31:107-18.
69. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-6.
70. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149:604-10.
71. Drazen JM, Israel E, Boushey HA et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841-7.
72. Wahedna I, Wong CS, Wisniewski AF, Pavord ID, Tattersfield AE Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis 1993; 148:707-12.
73. Broadley KJ Beta-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 2006; 533:15-27.
74. Sears MR, Taylor DR The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994; 11:259-83.
75. Taylor DR, Hannah D Management of beta-agonist overuse: why and how? J Allergy Clin Immunol 2008; 122:836-8.
76. Callaerts-Vegh Z, Evans KL, Dudekula N et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 2004; 101:4948-53.
77. Lin R, Peng H, Nguyen LP et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 2008; 21:115-24.
78. Nguyen LP, Omoluabi O, Parra S et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38:256-62.
79. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836-44.
80. Greening AP, Ind PW, Northfield M, Shaw G Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344:219-24.
81. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-11.
82. Castle W, Fuller R, Hall J, Palmer J Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-7.
83. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
84. Aaronson DW The "black box" warning and allergy drugs. J Allergy Clin Immunol 2006; 117:40-4.
85. Guo JJ, Tsai K, Kelton CML, Bian B, Wigle PR Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study. Ann Allergy Asthma Immunol 2011; 106:214-22.
86. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-4.
87. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-12.
88. Chowdhury BA Overview of the FDA background materials prepared for the meeting to discuss implications of the available data related to the safety of long-acting beta-agonists bronchodilators: Division Director Memorandum. Available at: (Accessed July, 2011).
89. Chowdhury BA, Seymour SM, Levenson MS Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011; 364:2473-5.
90. Chung LP, Waterer G, Thompson PJ Pharmacogenetics of beta2 adrenergic receptor gene polymorphisms, long-acting beta-agonists and asthma. Clin Exp Allergy 2011; 41:312-26.
91. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363:1715-26.
92. Kerstjens HA, Disse B, Schroder-Babo W et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128:308-14.
93. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-23.
94. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
95. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271-7.
96. de Marco R, Marcon A, Jarvis D et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 2006; 117:1249-56.
97. Naqvi M, Choudhry S, Tsai HJ et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allergy Clin Immunol 2007; 120:137-43.
98. den Otter I, Silva LF, Carvalho AL et al. High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. Clin Exp Allergy 2010; 40:1473-81.
99. Strunk RC, Bloomberg GR Omalizumab for asthma. N Engl J Med 2006; 354:2689-95.
100. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
101. Rodrigo GJ, Neffen H, Castro-Rodriguez JA Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28-35.
102. Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
103. Saha SK, Berry MA, Parker D et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121:685-91.
104. Ingram JL, Huggins MJ, Church TD et al. Airway fibroblasts in asthma manifest an invasive phenotype. Am J Respir Crit Care Med 2011; 183:1625-32.
105. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98. Epub 2011 Aug 3.
106. O'Driscoll BR, Powell G, Chew F et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39:1677-83.
107. Schwartz HJ, Citron KM, Chester EH et al. A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London. J Allergy Clin Immunol 1978; 62:9-14.
108. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002; 325:411-4.
109. Fairs A, Agbetile J, Hargadon B et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182:1362-8.
110. Greenberger PA Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685-92.
111. Ward GW Jr, Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol 1999; 104:541-6.
112. Denning DW, O'Driscoll BR, Powell G et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11-8.
113. Gore RB The utility of antifungal agents for asthma. Curr Opin Pulm Med 2010; 16:36-41.
114. Rackemann FM A working classification of asthma. Am J Med 1947; 3:601-6.
115. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5.
116. Samter M, Beers RF Jr Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975-83.
117. Szczeklik A, Nizankowska E Clinical features and diagnosis of aspirin induced asthma. Thorax 2000; 55(Suppl. 2):S42-4.
118. Delclaux C, Malinvaud D, Chevalier-Bidaud B, Callens E, Mahut B, Bonfils P Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis. Clin Exp Allergy 2008; 38:1140-7.
119. Ten Brinke A, Grootendorst DC, Schmidt JT et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109:621-6.
120. van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009; 124:615-7, 617.
121. Bresciani M, Paradis L, Des Roches A et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001; 107:73-80.
122. Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-13.
123. Dunlop G, Scadding GK, Lund VJ The effect of endoscopic sinus surgery on asthma: management of patients with chronic rhinosinusitis, nasal polyposis, and asthma. Am J Rhinol 1999; 13:261-5.
124. Ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-8.
125. Bousquet J, Bachert C, Canonica GW et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124:428-33.
126. Newman LJ, Platts-Mills TA, Phillips CD, Hazen KC, Gross CW Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. JAMA 1994; 271:363-7.
127. Ragab S, Scadding GK, Lund VJ, Saleh H Treatment of chronic rhinosinusitis and its effects on asthma. Eur Respir J 2006; 28:68-74.
128. Szczeklik A, Stevenson DD Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
129. Hope AP, Woessner KA, Simon RA, Stevenson DD Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123:406-10.
130. Shaker M, Lobb A, Jenkins P et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2008; 121:81-7.
131. Stevenson DD, Pleskow WW, Simon RA et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-7.
132. Dahlen B Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161:S137-41.
133. Dahlen SE, Malmstrom K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9-14.
134. Dahlen B, Nizankowska E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187-94.
135. Sorkness RL, Bleecker ER, Busse WW et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104:394-403.
136. Busacker A, Newell JD Jr, Keefe T et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135:48-56.
137. Hauber HP, Gotfried M, Newman K et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003; 112:58-63.
138. Bateman ED, Cheung D, Lapa e Silva J, Göhring UM, Schäfer M, Engelstätter R Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma. Pulm Pharmacol Ther 2008; 21:489-98.
139. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
140. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-8.
141. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8.
142. Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M, Djukanovic R The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16.
143. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601-5.
144. Walsh LJ, Wong CA, Oborne J et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56:279-84.
145. Hashimoto S, Ten Brinke A, Roldaan AC et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011; 66:514-20.
146. Davies H, Olson L, Gibson P Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; 2:CD000391.
147. Evans DJ, Cullinan P, Geddes DM Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; 2:CD002993.
148. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993; 147:398-404.
149. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996; 98:317-24.
150. Frew AJ, Plummeridge MJ Alternative agents in asthma. J Allergy Clin Immunol 2001; 108:3-10.
151. Niven AS, Argyros G Alternate treatments in asthma. Chest 2003; 123:1254-65.
152. Barnes PJ Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-8.
153. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-36.
154. Leckie MJ, Ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
155. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-93.
156. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
157. Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582-8.
158. Dixon AE, Holguin F, Sood A et al. An official American Thoracic Society Workshop report: obesity and asthma. Proc Am Thorac Soc 2010; 7:325-35.
159. Von Behren J, Lipsett M, Horn-Ross PL et al. Obesity, waist size and prevalence of current asthma in the California Teachers Study cohort. Thorax 2009; 64:889-93.
160. Mosen DM, Schatz M, Magid DJ, Camargo CA Jr The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008; 122:507-11.
161. Taylor B, Mannino D, Brown C, Crocker D, Twum-Baah N, Holguin F Body mass index and asthma severity in the National Asthma Survey. Thorax 2008; 63:14-20.
162. Peters JI, McKinney JM, Smith B, Wood P, Forkner E, Galbreath AD Impact of obesity in asthma: evidence from a large prospective disease management study. Ann Allergy Asthma Immunol 2011; 106:30-5.
163. Romagnoli I, Laveneziana P, Clini EM et al. Role of hyperinflation vs. deflation on dyspnoea in severely to extremely obese subjects. Acta Physiol (Oxf) 2008; 193:393-402.
164. Shore SA Obesity, airway hyperresponsiveness, and inflammation. J Appl Physiol 2010; 108:735-43.
165. Sabate JM, Jouet P, Merrouche M et al. Gastroesophageal reflux in patients with morbid obesity: a role of obstructive sleep apnea syndrome? Obes Surg 2008; 18:1479-84.
166. Stenius-Aarniala B, Poussa T, Kvarnström J, Grönlund E, Ylikahri M, Mustajoki P Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320:827-32.
167. Macgregor AM, Rand CS Gastric surgery in morbid obesity. Outcome in patients aged 55 years and older. Arch Surg 1993; 128:1153-7.
168. Reddy RC, Baptist AP, Fan Z, Carlin AM, Birkmeyer NJO The effects of bariatric surgery on asthma severity. Obes Surg 2011; 21:200-6.
169. Julien JY, Martin JG, Ernst P et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol 2009; 124:371-6.
170. Alkhalil M, Schulman ES, Getsy J Obstructive sleep apnea syndrome and asthma: the role of continuous positive airway pressure treatment. Ann Allergy Asthma Immunol 2008; 101:350-7.
171. Chan CS, Woolcock AJ, Sullivan CE Nocturnal asthma: role of snoring and obstructive sleep apnea. Am Rev Respir Dis 1988; 137:1502-4.
172. Lafond C, Series F, Lemiere C Impact of CPAP on asthmatic patients with obstructive sleep apnoea. Eur Respir J 2007; 29:307-11.
173. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergreen J Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290:66-72.
174. Harding SM, Guzzo MR, Richter JE The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162:34-9.
175. Gibson PG, Henry RL, Coughlan JL Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; 2:CD001496.
176. Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest 2005; 127:1227-31.
177. Mastronarde JG, Anthonisen NR, Castro M et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360:1487-99.
178. Kiljander TO, Junghard O, Beckman O, Lind T Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181:1042-8.
179. Douwes J, Gibson P, Pekkanen J, Pearce N Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57:643-8.
180. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213-4.
181. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532-9.
182. Gibson PG, Simpson JL, Saltos N Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119:1329-36.
183. Thomas RA, Green RH, Brightling CE et al. The influence of age on induced sputum differential cell counts in normal subjects. Chest 2004; 126:1811-4.
184. Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002; 112:446-52.
185. Gupta S, Siddiqui S, Haldar P et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136:1521-8.
186. Berry M, Morgan A, Shaw DE et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62:1043-9.
187. Johnston SL, Martin RJ Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med 2005; 172:1078-89.
188. von Hertzen L, Töyrylä M, Gimishanov A et al. Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999; 29:522-8.
189. Black PN, Scicchitano R, Jenkins CR et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15:254-9.
190. Ten Brinke A, van Dissel JT, Sterk PJ, Zwinderman AH, Rabe KF, Bel EH Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001; 107:449-54.
191. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-55.
192. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708.
193. Thomas PS, Yates DH, Barnes PJ Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152:76-80.
194. Brightling C, Berry M, Amrani Y Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121:5-10.
195. Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-8.
196. Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549-58.
197. Cox PG, Miller J, Mitzner W, Leff AR Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24:659-63.
198. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006; 173:965-9.
199. Cox G, Thomson NC, Rubin AS et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327-37.
200. Castro M, Rubin AS, Laviolette M et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181:116-24.
201. Thomson NC, Rubin AS, Niven RM et al. Long-term (5 year) safety of bronchial thermoplasty: asthma Intervention Research (AIR) trial. BMC Pulm Med 2011; 11:8.
202. Karagiannidis C, Hense G, Rueckert B et al. High-altitude climate therapy reduces local airway inflammation and modulates lymphocyte activation. Scand J Immunol 2006; 63:304-10.
203. Rijssenbeek-Nouwens LH, Bel EH High-altitude treatment: a therapeutic option for patients with severe, refractory asthma? Clin Exp Allergy 2011; 41:775-82.
204. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137:1410-6.